New Points of Departure for More Global Influenza Vaccine Use

New Points of Departure for More Global Influenza Vaccine Use

Each year, influenza causes a significant acute respiratory disease burden. In addition, influenza pandemics periodically occur. Annual vaccination is the best tool for influenza prevention, but its effectiveness can vary from year to year. The narrow specificity of conventional vaccines and the dru...

Full description

Bibliographic Details
Main Author: Irina Kiseleva
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Vaccines
Subjects:
influenza
inactivated vaccines
live attenuated vaccines
next-generation vaccines
synthetic vaccines
cross protectivity
Online Access:https://www.mdpi.com/2076-393X/8/3/410
id doaj-134ef591f5364a2792ad6e4433b5fe58
record_format Article
spelling doaj-134ef591f5364a2792ad6e4433b5fe582020-11-25T02:48:06ZengMDPI AGVaccines2076-393X2020-07-01841041010.3390/vaccines8030410New Points of Departure for More Global Influenza Vaccine UseIrina Kiseleva0Department of Virology, Federal State Budgetary ScYientific Institution, Institute of Experimental Medicine, 197376 St Petersburg, RussiaEach year, influenza causes a significant acute respiratory disease burden. In addition, influenza pandemics periodically occur. Annual vaccination is the best tool for influenza prevention, but its effectiveness can vary from year to year. The narrow specificity of conventional vaccines and the drug resistance of currently circulating viruses reduce the effectiveness of prophylaxis and treatment and require the development of new broad-spectrum preparations. Furthermore, the challenge of creating a highly effective universal influenza vaccine takes on renewed intensity in the face of the COVID-19 pandemic.https://www.mdpi.com/2076-393X/8/3/410influenzainactivated vaccineslive attenuated vaccinesnext-generation vaccinessynthetic vaccinescross protectivity
collection DOAJ
language English
format Article
sources DOAJ
author Irina Kiseleva
spellingShingle Irina Kiseleva
New Points of Departure for More Global Influenza Vaccine Use
Vaccines
influenza
inactivated vaccines
live attenuated vaccines
next-generation vaccines
synthetic vaccines
cross protectivity
author_facet Irina Kiseleva
author_sort Irina Kiseleva
title New Points of Departure for More Global Influenza Vaccine Use
title_short New Points of Departure for More Global Influenza Vaccine Use
title_full New Points of Departure for More Global Influenza Vaccine Use
title_fullStr New Points of Departure for More Global Influenza Vaccine Use
title_full_unstemmed New Points of Departure for More Global Influenza Vaccine Use
title_sort new points of departure for more global influenza vaccine use
publisher MDPI AG
series Vaccines
issn 2076-393X
publishDate 2020-07-01
description Each year, influenza causes a significant acute respiratory disease burden. In addition, influenza pandemics periodically occur. Annual vaccination is the best tool for influenza prevention, but its effectiveness can vary from year to year. The narrow specificity of conventional vaccines and the drug resistance of currently circulating viruses reduce the effectiveness of prophylaxis and treatment and require the development of new broad-spectrum preparations. Furthermore, the challenge of creating a highly effective universal influenza vaccine takes on renewed intensity in the face of the COVID-19 pandemic.
topic influenza
inactivated vaccines
live attenuated vaccines
next-generation vaccines
synthetic vaccines
cross protectivity
url https://www.mdpi.com/2076-393X/8/3/410
work_keys_str_mv AT irinakiseleva newpointsofdepartureformoreglobalinfluenzavaccineuse
_version_ 1724749966129233920

Similar Items